

Treatment Of Melanoma With Ferroptosis Inducing Agents

Tech ID: 28887 / UC Case 2017-879-0

SUMMARY

UCLA researchers in the Departments of Molecular and Medical Pharmacology and Medicine have developed a novel method to treat melanoma.

BACKGROUND

Immune checkpoint blockade immunotherapy with anti-PD1 antibody is the preferred treatment for patients with metastatic melanoma that has resisted other therapies. However, there remains a subset of patients that does not respond to or relapses following this therapeutic strategy, as de-differentiation of melanoma cells is known to increase resistance to conventional immunotherapies. So far there is no therapy specifically tailored to target these immunotherapy-resistant de-differentiated melanoma cells.

INNOVATION

Researchers at UCLA have developed a method to treat melanoma that resists conventional immune checkpoint blockade immunotherapy by using ferroptosis-inducing drugs. Ferroptosis is a type of cell death resulting from accumulation of reactive oxygen species that degrade lipids in the cell membrane. De-differentiating cells, such as the immunotherapy-resistant or kinase inhibitor-resistant melanoma, are highly susceptible to ferroptosis. Combination treatment with ferroptosis-inducing agents can be a valuable, new synergistic approach for overcoming resistance to melanoma therapy.

APPLICATIONS

- ▶ Combinatorial therapy for cancer treatment
- ▶ Stratification method for skin cancer treatment
- ▶ Screening method for immunotherapy-resistant or kinase inhibitor-resistant melanomas

ADVANTAGES

- ▶ Specifically targets a subset of cancer cells that resist other forms of therapy
- ▶ Combinatorial use with conventional immunotherapy or kinase inhibitors prevents tumor escape due to de-differentiation

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Published Application	20200163966	05/28/2020	2017-879
European Patent Office	Published Application	3645739	05/06/2020	2017-879

RELATED MATERIALS

- ▶ Titz, Bjoern, et al. "JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma." Cell discovery 2 (2016): 16028.
- ▶ Zaretsky, Jesse M., et al. "Mutations associated with acquired resistance to PD-1 blockade in melanoma." New England Journal of Medicine 375.9 (2016): 819-829.
- ▶ Müller, Judith, et al. "Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma." Nature communications 5 (2014): 5712.

CONTACT

UCLA Technology Development Group
 ncd@tdg.ucla.edu
 tel: 310.794.0558.



INVENTORS

- ▶ Graeber, Thomas G.

OTHER INFORMATION

KEYWORDS

melanoma resistant ferroptosis skin cancer drugs immunotherapy PD1 CTLA4 combination immune checkpoint blockade, MAP kinase pathway, MAPK, BRAF inhibitors, MEK inhibitors

CATEGORIZED AS

- ▶ **Medical**
 - ▶ Disease: Cancer
 - ▶ Disease: Dermatology
 - ▶ Therapeutics

RELATED CASES

2017-879-0

▶ Tsoi, J, Robert, L, Paraiso, K, Galvan, C, Sheu, K, Lay, J, Wong, DJL, Atefi, M, Shirazi, R, Wang, X, Braas, D, Grasso, CS, Palaskas, N, Ribas, A, Graeber, TG. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. *Cancer Cell*. 2018 May 14;33(5):890-904.e5.

▶ Kemeny LV, Fisher DE. Targeting the (Un)differentiated State of Cancer. *Cancer Cell*. 2018 May 14;33(5):793–795.

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ Identification Of Pan-Cancer Small Cell Neuroendocrine Phenotypes And Vulnerabilities
- ▶ Statistical Comparison of Rank Lists and Molecular Profiles

Gateway to Innovation, Research and Entrepreneurship

UCLA Technology Development Group

10889 Wilshire Blvd., Suite 920, Los Angeles, CA 90095

tdg.ucla.edu

Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu

© 2017 - 2020, The Regents of the University of California

[Terms of use](#)

[Privacy Notice](#)

